ChromaDex Achieves New Regulatory Milestones in the European Union & Australia

Tailwinds' Take: we remain believers in Tru Niagen and think it has a bright future. When we think the company is financed through to...

Visions of 2020

This last week was actually a very good week for the Tailwinds' portfolio. Despite the overall quiet of a holiday week (or maybe because...

LD Micro Recap and Other Thoughts From Last Week

LA is usually a great place to be in December, compared to the rest of the nation. With the weather being generally sunny and...

Several Thoughts On Micro-Cap Stocks I Follow

The market seems took a little hit this week, then bounced back. The net result of which was the wind coming out of the...

November Review

Was my sigh of relief audible everywhere? I've been doing this long enough to know that markets are cyclical and that the point of...

Deep Fried Turkey

Those who know me well are well aware that Wednesdays are my favorite night of the week. That's the night I go out mountain...

European Commission Votes in Favor on Nicotinamide Riboside Chloride as a Novel Food

LOS ANGELES, Nov. 20, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced that European Member States have voted in favor of listing Nicotinamide...

Recapping The Recent Earnings Reports

The last couple weeks have seen a slew of earnings reports and, more importantly, investor update calls from companies in the Tailwinds Universe. Importantly...

ChromaDex Corporation Reports Third Quarter 2019 Financial Results

Third Quarter 2019 Highlights vs. Third Quarter 2018 Strong growth in net sales to $12.1 million, improved gross margin, and significantly improved marketing efficiency...

ChromaDex Statement Regarding the October 9th Order in the Central District of California Litigation

Tailwinds' Take: not a moment of shining glory for the court system. This whole case is an ongoing fiasco that is just wasting dual...

ChromaDex Announces $7 Million Private Placement of Common Stock

Tailwinds' Take: continued strategic interest in CDXC bodes well for future market acceptance of Tru Niagen. Revenues beat last Q and are in a...

Recapping The Week That Was…And Looking Towards Next

This was a very hectic week in the market, with major swings in the indexes and in our universe of smaller companies. Earnings season...

ChromaDex Corporation Reports Second Quarter 2019 Financial Results

Tailwinds' Take: great incremental growth. LOS ANGELES, Aug. 07, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2019 financial results. “We successfully continue...

A Shallow Dive From The Deep South

In what is shaping up as a never-ending quest to provide newsletter coverage from anyplace not named "home", this week's letter comes from Raleigh,...

ChromaDex Corporation Reports First Quarter 2019 Financial Results

First Quarter 2019 Highlights vs. First Quarter 2018 Strong start to the year with $10.0 million of net sales, higher gross margins and increased marketing efficiency ...

ChromaDex Announces $10 Million Issuance of Convertible Notes

LOS ANGELES, May 09, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible...

ChromaDex Drives Global Expansion Strategy for TRU NIAGEN® with Specialty Retail Launch and Expanded...

LOS ANGELES, April 15, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the latest milestone in its global expansion strategy for TRU NIAGEN®, with a strategic deal...

New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide...

LOS ANGELES, April 09, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a new preclinical study showed that supplementation with the unique B3 vitamin...

ChromaDex Corporation Reports 2018 Financial Results

Fourth Quarter 2018 Highlights vs. Fourth Quarter 2017 Entered into a global license and supply agreement with Nestlé Health Science (“NHSc”), which provides NHSc...

ChromaDex Corp. and Nestlé Health Science Enter Global Commercial License and Supply Agreement for...

Tailwinds' Take: this press release has a big "WOW" factor. If the market was looking for validation of Tru Niagen, Nestle can...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.